Physician profile
Robert Emil Ettlinger
NPI 1740383744
$231,756.63
in general payments reported to CMS, 2019-2025
16 companies · $34.07 in 2025
The $34.07 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125K · 2020: $23K · 2021: $35K · 2022: $24K · 2023: $13K · 2024: $11K · 2025: $34.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $1,890 · Consulting Fee: $1,620 · Travel and Lodging: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,852.00 |
| Food and Beverage | $1,889.91 |
| Consulting Fee | $1,620.00 |
| Travel and Lodging | $1,028.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $68,256.53 | 2019-2024 | Tavneos, Otezla, Amjevita |
| Celgene Corporation | $35,871.44 | 2019 | |
| Pfizer INC. | $34,871.28 | 2019-2023 | |
| Aurinia Pharma U.S., INC. | $25,725.17 | 2021-2023 | Lupkynis |
| Regeneron Healthcare Solutions, INC. | $21,584.58 | 2019 | |
| Genzyme Corporation | $21,217.40 | 2020-2024 | |
| Glaxosmithkline, LLC. | $15,314.67 | 2021-2022 | |
| Lilly USA, LLC | $6,231.02 | 2019-2022 | |
| Janssen Biotech, INC. | $1,957.61 | 2023 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $282.89 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $111.06 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $95.51 | 2019-2024 | Tremfya |
| Sanofi-Aventis U.S. LLC | $89.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $89.67 | 2020-2021 | |
| Abbvie INC. | $34.07 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $23.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ettlinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.